Patients must have histologically/pathologically confirmed colon adenocarcinoma (T1-3, N1/N1c) with R0 resection accordingly to AJCC 8th edition criteria. NOTE: Patients with pathologic stages II or IIIC colon adenocarcinoma with R0 resection who have a commercially obtained Signatera™ ctDNA+ve assay result post-operatively meeting all timelines and eligibility requirements otherwise, are eligible for enrollment and inclusion in Cohort B.
No radiographic evidence of overt metastatic disease
Distal extent of tumor must be greater than or equal to 12cm from the anal verge
Must have had curative resection (en bloc)
Resected tumor specimen and blood must have central testing for ctDNA useing the Signatera assay
Must be microsatellite stable or have intact mismatch proteins